Semaglutide is a Glucagon-like peptide-1 (GLP-1) produced by the
gut. It increases insulin production, a hormone that lowers the blood
sugar level while inhibiting glucagon secretion, which is a hormone
that raises blood sugar, reduces appetite and energy intake while
delaying gastric emptying. It was first developed in 2012 as a longer-
acting option to Liraglutide. In 2017 this drug was approved as an
anti-diabetic medication used to treat type 2 diabetes and obesity.
In June 2021, it got approved for chronic weight management in
obese individuals with a (BMI) ≥ 30 kg/m2) or overweight (initial BMI
≥ 27 kg/m2) with at least one weight-related comorbidity.
Levocarnitine is an amino acid that benefits energy levels by
transporting fatty acids into the mitochondria, where they can be
used as energy. For this reason, many take carnitine as a weight-loss
supplement to help accelerate fat burning.
This GPL1 medication reduces food intake by lowering
appetite, slows food digestion in the stomach, decrease body fat percentage,
Weight loss, decreased cardiovascular outcomes in
patients with type 2 diabetes and cardiovascular disease plus
Lowers HbA1c levels.
It Enhances the growth of β cells in the